March 6, 2017

For today's bulletin, we take a look at our latest top-five STRONG BUY upgrade list and provide a link to download a FREE STOCK REPORT on Health Insurance Innovations (HIIQ)

VALUATION WARNING: Overvalued stocks now make up 68.51% of our stocks assigned a valuation and 32.53% of those equities are calculated to be overvalued by 20% or more. Sixteen sectors are calculated to be overvalued.

If you cannot display this bulletin properly, GO HERE

Get Healthy

--Health Insurance Innovations Leads ValuEngine Upgrade List

For today's edition of our upgrade list, we used our website's advanced screening functions to search for UPGRADES to BUY or STRONG BUY with complete forecast and valuation data. They are presented by one-month forecast return. Health Insurance Innovations, Inc. (HIIQ) is our top-rated upgrade this week and it is a STRONG BUY. Our other picks are also STRONG BUY stocks with the exception of NOAH and EPR--which are BUY-rated.

Health Insurance Innovations, Inc. (HIIQ) operates as a developer and administrator of web-based individual health insurance plans and ancillary products. Its product portfolio consists of short-term medical plans, accident, sickness & hospital medical plans, ancillary insurance, life insurance, lifestyle and discount services. Health Insurance Innovations, Inc. is based in Tampa, Florida.

The company reported Q4 2016 a loss of $0.04/share last week with earnings--adjusted--of $0.35/share. Revenue was $51.4 million for the reported quarter. Yearly figures included a profit of $4.5 million/share on revenue of $184.5 million. The companies shares have traded is a narrow range since the start of 2017.

Analysts coverage is a mixed bag, with some rating it a BUY and others a HOLD. We have a STRONG BUY on the firm with a target price of $19.20 for the year. This is in line with an average target price of $20 from other analysts.

Of course, almost everything health-care related is up-in-the-air these days as the new Trump administration and their GOP allies in the US Congress are unable/unwilling to deal with ACA/"Obamacare" reforms now that they hold complete power in DC. Their long-term efforts to remove the expanded health-care coverage for millions of Americans have faltered now that the proverbial rubber has met the proverbial road.

It remains to be seen what, if any tweaks will be made to the US health-care system. Trump himself has claimed that "nobody knew health care could be so complicated"--and he was met with widespread derision.

However, "complicated" is a good descriptor. Investors should remain cautious with health care stocks due to possible changes from Washington. But, we are convinced that with each passing day an outright repeal of the ACA seems far less likely. That means that innovators in the field may be well-positioned to profit from more business-friendly reforms from allies in Washington

Below is today's data on Health Insurance Innovations, Inc. (HIIQ):

VALUENGINE RECOMMENDATION: ValuEngine updated its recommendation from BUY to STRONG BUY for Avis Health Insurance Innovations on 2017-02-24. Based on the information we have gathered and our resulting research, we feel that Health Insurance Innovations has the probability to OUTPERFORM average market performance for the next year. The company exhibits ATTRACTIVE P/E Ratio and Price Sales Ratio.

You can download a free copy of detailed report on Health Insurance Innovations, Inc. (HIIQ) from the link below.

ValuEngine Forecast
	Target Price*	Expected Return
1-Month	17.00	1.19%
3-Month	17.11	1.82%
6-Month	17.66	5.09%
1-Year	19.20	14.28%
2-Year	17.57	4.55%
3-Year	18.71	11.38%

Valuation & Rankings
Valuation	12.56% overvalued	Valuation Rank(?)	46
1-M Forecast Return	1.19%	1-M Forecast Return Rank	99
12-M Return	182.35%	Momentum Rank(?)	97
Sharpe Ratio	0.12	Sharpe Ratio Rank(?)	59
5-Y Avg Annual Return	9.07%	5-Y Avg Annual Rtn Rank	71
Volatility	75.96%	Volatility Rank(?)	21
Expected EPS Growth	6.93%	EPS Growth Rank(?)	34
Market Cap (billions)	0.25	Size Rank	44
Trailing P/E Ratio	14.08	Trailing P/E Rank(?)	82
Forward P/E Ratio	13.17	Forward P/E Ratio Rank	71
PEG Ratio	2.03	PEG Ratio Rank	24
Price/Sales	1.48	Price/Sales Rank(?)	58
Market/Book	8.81	Market/Book Rank(?)	16
Beta	0.28	Beta Rank	72
Alpha	1.07	Alpha Rank	98

DOWNLOAD A FREE SAMPLE OF OUR HEALTH INSURANCE INNOVATIONS (HIIQ) REPORT BY CLICKING HERE

ValuEngine tracks more than 7000 US equities, ADRs, and foreign stock which trade on US exchanges as well as @1000 Canadian equities.  When EPS estimates are available for a given equity, our model calculates a level of mispricing or valuation percentage for that equity based on earnings estimates and what the stock should be worth if the market were totally rational and efficient--an academic exercise to be sure, but one which allows for useful comparisons between equities, sectors, and industries. Using our Valuation Model, we can currently assign a VE valuation calculation to more than 2800 stocks in our US Universe.

We combine all of the equities with a valuation calculation to track market valuation figures and use them as a metric for making calls about the overall state of the market.  Two factors can lower these figures-- a market pullback, or a significant rise in EPS estimates.

We also use trading data to provide forecast estimates for a variety of time horizons for almost ever equity in our database. Our Buy/Sell/Hold recommendations are based upon the 1-year forecast return figure. Using valuation and forecast figures, you can rank and rate our covered stocks against each other, to find out, in an objective and systematic way, the most attractive investment targets based on your own risk/reward parameters. We re-calculate the entire database every trading day, so you are assured that every proprietary valuation and forecast datapoint is as up-to-date as possible.